STEK · Stemtech Corp
$0.00
+0.00 (+0.00%)
At close · Sep 3
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has experienced recurring net losses and negative cash flows from operations since inception and has an accumulated deficit of approximately $36.3 million and a working capital deficiency of approximately $10.5 million at June 30, 2026. The Company has funded its activities to date almost exclusively from debt and equity financing. These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$299,703
Shares
3.00B
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.00
Open$0.00
Day$0.00–0.00
52W close$0.00–0.02
Avg vol 30d9.0M
Short int373K · 0.0% float · 1.0d
Short vol7%
DataNov 2021–Sep 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.40M
Trailing 12 months
Net income (TTM)
−$3.84M
Trailing 12 months
Revenue growth YoY
-9.8%
Year over year
Operating margin
-100.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-109.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$4.15M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,358.4%
Year over year · more shares
Price change (1Y)
-99.3%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.47
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−83%
below
Price vs 50-day avg
0%
above
RSI (14)
40
neutral
MACD trend
Positive
52-week position
0%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
−67%
trailing
YTD return
−88%
this year
Relative strength
−83%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.01% of float · ▲ +273.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
33
low risk · 0–100
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
47%
contracting
EPS growth
+33%
Y/Y
Free cash flow
$-483.6K
Balance sheet
$3.9M
net debt
Quant / Vol
risk profile
Volatility
443%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
0.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−83%
Bearish
Price vs 50-day avg
0%
Neutral
RSI (14)
40
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.01% of float · ▲ +273.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $0
vs 200-day avg -83%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STEK
this stock
Stemtech Corp
|
$299,703 | -87.5% | +7.9% | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.66B | +20.0% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$47.50B | -2.8% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$43.03B | +17.3% | +4.3% | 60.5 | 3.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STEK | +0.0% | +0.0% | -66.7% | +0.0% | -87.5% |
| SPY | +0.3% | +0.6% | +16.7% | +0.8% | +13.4% |
| vs SPY | -0.3% | -0.6% | -83.4% | -0.8% | -100.9% |